58
views
0
recommends
+1 Recommend
0 collections
    11
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Genetic association of zinc transporter 8 (ZnT8) autoantibodies in type 1 diabetes cases

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Aims/hypothesis

          Autoantibodies to zinc transporter 8 (ZnT8A) are associated with risk of type 1 diabetes. Apart from the SLC30A8 gene itself, little is known about the genetic basis of ZnT8A. We hypothesise that other loci in addition to SLC30A8 are associated with ZnT8A.

          Methods

          The levels of ZnT8A were measured in 2,239 British type 1 diabetic individuals diagnosed before age 17 years, with a median duration of diabetes of 4 years. Cases were tested at over 775,000 loci genome wide (including 53 type 1 diabetes associated regions) for association with positivity for ZnT8A. ZnT8A were also measured in an independent dataset of 855 family members with type 1 diabetes.

          Results

          Only FCRL3 on chromosome 1q23.1 and the HLA class I region were associated with positivity for ZnT8A. rs7522061T>C was the most associated single nucleotide polymorphism (SNP) in the FCRL3 region ( p = 1.13 × 10 −16). The association was confirmed in the family dataset ( p ≤ 9.20 × 10 −4). rs9258750A>G was the most associated variant in the HLA region ( p = 2.06 × 10 −9 and p = 0.0014 in family cases). The presence of ZnT8A was not associated with HLA-DRB1, HLA-DQB1, HLA-A, HLA-B or HLA-C ( p > 0.05). Unexpectedly, the two loci associated with the presence of ZnT8A did not alter risk of having type 1 diabetes, and the 53 type 1 diabetes risk loci did not influence positivity for ZnT8A, despite them being disease specific.

          Conclusions/interpretation

          ZnT8A are not primary pathogenic factors in type 1 diabetes. Nevertheless, ZnT8A testing in combination with other autoantibodies facilitates disease prediction, despite the biomarker not being under the same genetic control as the disease.

          Electronic supplementary material

          The online version of this article (doi:10.1007/s00125-012-2540-2) contains peer-reviewed but unedited supplementary material, which is available to authorised users.

          Related collections

          Most cited references26

          • Record: found
          • Abstract: found
          • Article: not found

          A genome-wide association study identifies novel risk loci for type 2 diabetes.

          Type 2 diabetes mellitus results from the interaction of environmental factors with a combination of genetic variants, most of which were hitherto unknown. A systematic search for these variants was recently made possible by the development of high-density arrays that permit the genotyping of hundreds of thousands of polymorphisms. We tested 392,935 single-nucleotide polymorphisms in a French case-control cohort. Markers with the most significant difference in genotype frequencies between cases of type 2 diabetes and controls were fast-tracked for testing in a second cohort. This identified four loci containing variants that confer type 2 diabetes risk, in addition to confirming the known association with the TCF7L2 gene. These loci include a non-synonymous polymorphism in the zinc transporter SLC30A8, which is expressed exclusively in insulin-producing beta-cells, and two linkage disequilibrium blocks that contain genes potentially involved in beta-cell development or function (IDE-KIF11-HHEX and EXT2-ALX4). These associations explain a substantial portion of disease risk and constitute proof of principle for the genome-wide approach to the elucidation of complex genetic traits.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes.

            Type 1 diabetes (T1D) results from progressive loss of pancreatic islet mass through autoimmunity targeted at a diverse, yet limited, series of molecules that are expressed in the pancreatic beta cell. Identification of these molecular targets provides insight into the pathogenic process, diagnostic assays, and potential therapeutic agents. Autoantigen candidates were identified from microarray expression profiling of human and rodent pancreas and islet cells and screened with radioimmunoprecipitation assays using new-onset T1D and prediabetic sera. A high-ranking candidate, the zinc transporter ZnT8 (Slc30A8), was targeted by autoantibodies in 60-80% of new-onset T1D compared with <2% of controls and <3% type 2 diabetic and in up to 30% of patients with other autoimmune disorders with a T1D association. ZnT8 antibodies (ZnTA) were found in 26% of T1D subjects classified as autoantibody-negative on the basis of existing markers [glutamate decarboxylase (GADA), protein tyrosine phosphatase IA2 (IA2A), antibodies to insulin (IAA), and islet cytoplasmic autoantibodies (ICA)]. Individuals followed from birth to T1D showed ZnT8A as early as 2 years of age and increasing levels and prevalence persisting to disease onset. ZnT8A generally emerged later than GADA and IAA in prediabetes, although not in a strict order. The combined measurement of ZnT8A, GADA, IA2A, and IAA raised autoimmunity detection rates to 98% at disease onset, a level that approaches that needed to detect prediabetes in a general pediatric population. The combination of bioinformatics and molecular engineering used here will potentially generate other diabetes autoimmunity markers and is also broadly applicable to other autoimmune disorders.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Type 1 diabetes: new perspectives on disease pathogenesis and treatment.

              As our knowledge of type 1 (insulin-dependent) diabetes increases, so does our appreciation for the pathogenic complexity of this disease and the challenges associated with its treatment. Many new concepts about the pathogenesis of this disorder have arisen. The role of genetics versus environment in disease formation has been questioned, and the basis on which type 1 diabetes is characterised and diagnosed is the subject of much debate. Additionally, the care and treatment of patients with type 1 diabetes has seen a rapid evolution; with genetically engineered insulins, glucose monitoring devices, and algorithms all contributing to a decrease in disease-related complications. We focus this seminar on these changing views, and offer a new perspective on our understanding of the pathogenesis of type 1 diabetes and on principles for therapeutic management of patients with this disorder.
                Bookmark

                Author and article information

                Contributors
                Joanna.Howson@cimr.cam.ac.uk
                John.Todd@cimr.cam.ac.uk
                Journal
                Diabetologia
                Diabetologia
                Diabetologia
                Springer-Verlag (Berlin/Heidelberg )
                0012-186X
                1432-0428
                12 April 2012
                12 April 2012
                July 2012
                : 55
                : 7
                : 1978-1984
                Affiliations
                [1 ]Juvenile Diabetes Research Foundation/Wellcome Trust Diabetes and Inflammation Laboratory, Cambridge Institute for Medical Research, Department of Medical Genetics, University of Cambridge, Addenbrooke’s Hospital, Hills Road, Cambridge, CB2 0XY UK
                [2 ]Forschergruppe Diabetes, Munich University of Technology, Munich, Germany
                [3 ]Barbara Davis Diabetes Centre, University of Colorado, Denver, CO USA
                [4 ]Centre for Regenerative Therapies, Dresden University of Technology, Dresden, Germany
                [5 ]Institute of Diabetes Research, Helmholtz Centre Munich, Neuherberg, Germany
                Article
                2540
                10.1007/s00125-012-2540-2
                3369141
                22526605
                44504fa5-5c58-4461-8ed4-512273b75b3f
                © The Author(s) 2012
                History
                : 23 December 2011
                : 23 February 2012
                Categories
                Article
                Custom metadata
                © Springer-Verlag 2012

                Endocrinology & Diabetes
                slc30a8,zinc transporter 8,autoantibody,fcrl3,mhc,type 1 diabetes,hla
                Endocrinology & Diabetes
                slc30a8, zinc transporter 8, autoantibody, fcrl3, mhc, type 1 diabetes, hla

                Comments

                Comment on this article